AIA Group Ltd Increases Stock Holdings in CVS Health Corporation $CVS

AIA Group Ltd raised its position in CVS Health Corporation (NYSE:CVS) by 104.8% in the 1st quarter, Holdings Channel reports. The fund owned 177,654 shares of the pharmacy operator’s stock after purchasing an additional 90,901 shares during the period. AIA Group Ltd’s holdings in CVS Health were worth $12,759,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Swiss RE Ltd. acquired a new stake in CVS Health during the 4th quarter valued at $26,000. Sankala Group LLC acquired a new position in CVS Health in the 4th quarter worth $28,000. Caitong International Asset Management Co. Ltd boosted its position in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 281 shares during the last quarter. Mcguire Capital Advisors Inc. acquired a new stake in shares of CVS Health during the fourth quarter valued at about $28,000. Finally, Ares Financial Consulting LLC acquired a new stake in shares of CVS Health during the fourth quarter valued at about $29,000. 80.66% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This trade represents a 24.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,441,551 shares of company stock valued at $323,703,977 over the last ninety days. Company insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. HSBC reiterated a “hold” rating and issued a $103.00 price target on shares of CVS Health in a research note on Monday, July 6th. Wells Fargo & Company upped their target price on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Piper Sandler reissued an “overweight” rating and set a $113.00 price target on shares of CVS Health in a research report on Monday, June 1st. JPMorgan Chase & Co. lifted their price target on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Finally, Argus upped their price target on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a report on Thursday, May 14th. Twenty-one analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $105.38.

CVS Health Price Performance

Shares of NYSE CVS opened at $107.36 on Friday. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $108.97. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $136.99 billion, a price-to-earnings ratio of 47.30, a price-to-earnings-growth ratio of 1.05 and a beta of 0.61. The business has a 50 day simple moving average of $98.97 and a 200-day simple moving average of $85.13.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the business posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities research analysts expect that CVS Health Corporation will post 7.46 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.5%. CVS Health’s payout ratio is 117.18%.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS opened its first pharmacy-focused location in Houston and plans to roll out nearly 20 similar sites, signaling an effort to expand access to in-person pharmacy care and strengthen its retail footprint. CVS Pharmacy® celebrates opening of first pharmacy-focused location in Houston
• Positive Sentiment: Management reiterated a constructive stance on GLP-1 drugs and pharmacy economics, with CEO comments highlighting that insurers may eventually cover weight-loss drugs more broadly once prices fall, reinforcing CVS’s role in cost management and pharmacy benefit services. CVS Health CEO David Joyner warns private insurers won’t cover GLP-1s for weight loss until drug prices drop
• Positive Sentiment: CVS also floated cost-saving solutions and a settlement in Georgia that could reduce prescription costs for some patients, which may improve public perception and support demand for its pharmacy services. New CVS settlement could lower prescription costs for some Georgians
• Neutral Sentiment: Coverage around CVS education benefits and talent development highlights workforce stability, but it is unlikely to have an immediate impact on the stock. At CVS, education benefits strengthen talent pipelines
• Neutral Sentiment: Broader analyst and media discussion of CVS’s dividend and GLP-1 strategy has helped reinforce the investment case, but this appears more supportive than a near-term catalyst. How Investors May Respond To CVS (CVS) Dividend Move And GLP‑1 Strategy Across Its Health Platform

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.